77results about How to "Induce apoptosis" patented technology

The invention discloses a PARP1 selective protein degradation agent and an application of the PARP1 selective protein degradation agent in tumor resistance. The degradation agent has the following structural formula. Wherein the 3-ethyl-7-((4-(pyridine-3-yl) piperazine-1-yl) methyl) quinoxaline-2 (1H)-ketone part is a PARP1 target protein ligand, and L is a connecting unit; and B is an E3 ubiquitin ligase ligand. The PARP1 selective protein degradation agent prepared by the preparation method disclosed by the invention can be used for effectively degrading PARP1 protein, inhibiting cell proliferation and inducing tumor cell apoptosis. Meanwhile, when the compound is combined with chemotherapeutic drugs, the effect of enhancing the chemotherapeutic effect is achieved, almost no physiological toxicity exists, and the compound is expected to provide an ideal way for improving treatment of various diseases caused by PARP1 excessive activation. # imgabs0 #

The invention provides application of hypericin nanoparticles subjected to photodynamic treatment in preparation of a medicine for inhibiting liver cancer cells. The hypericin nanoparticles (HC-NPs) are formed by wrapping a traditional Chinese medicine monomer hypericin (HC) with distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000). The hypericin nano-particles provided by the invention have an obvious inhibition effect on liver cancer cells under a specific illumination condition, so that the expression of the gene SERPINE1 is up-regulated in a time-dependent and dose-dependent manner. The gene participates in regulation of biological behaviors of liver cancer, and provides a new view angle for treatment of liver cancer.

The invention belongs to the field of tumor drugs, and discloses a radioactive hydrogel based on crosslinking of sodium alginate and metal ions and a preparation method and application thereof.The preparation method of the radioactive hydrogel comprises the following steps that lutetium chloride and metal ions are mixed, and a metal ion mixed solution is obtained; doping 177Lu radioactive isotope into the obtained metal ion mixed solution to obtain a metal ion cross-linking agent; and injecting a metal ion cross-linking agent into the sodium alginate solution under a vortex condition, centrifuging, and discarding the supernatant to obtain the radioactive hydrogel. The radioactive hydrogel (177Lu-RH) provided by the invention has good in-tumor colonization capability, can be directly injected into a tumor to realize local radiotherapy, has good radioactive stability, and can be stably retained at a tumor part for more than 120 hours, so that the stability of radioactive labeling in a treatment process is ensured.

The invention relates to the field of biological medicines, in particular to application of hypericin to preparation of a medicine for treating liver cancer. The invention provides application of hypericin in preparation of a medicine for treating liver cancer and a pharmaceutical composition containing the hypericin. The inventor finds that hypericin is used as a traditional Chinese medicine compound, in-vitro experiments prove that hypericin can inhibit liver cancer cell proliferation, inhibit liver cancer cell migration and induce liver cancer cell apoptosis, in-vivo experiments prove that hypericin can significantly inhibit liver tumor cell growth in mice, and it is indicated that hypericin can treat liver cancer. The traditional Chinese medicine composition can be used as a component in medicines for treating liver cancer.

The invention relates to the technical field of health-care products, in particular to a health-care product rich in momordica charantia polypeptide and capable of regulating blood sugar metabolism and promoting insulin secretion, momordica charantia polypeptide can stimulate pancreatic beta cells to secrete insulin, and insulin is the only hormone capable of reducing blood sugar in a human body. The balsam pear polypeptide component in the balsam pear extract is specially used for reducing the blood sugar level and improving related health problems, the application of the balsam pear polypeptide in the health care product can effectively regulate the blood sugar metabolism of a human body and promote the secretion of insulin, and the balsam pear polypeptide stimulates pancreas islet beta cells to promote the secretion of insulin. In addition, the balsam pear polypeptide can improve the insulin resistance, increase the number of insulin receptors or enhance the activity of the insulin receptors, so that the body cells are more sensitive to the insulin, the uptake and utilization of glucose are promoted, and the abnormal increase of the blood glucose level is avoided.

The invention belongs to the technical field of nanogel preparations, and particularly relates to application of nanogel to preparation of anti-tumor drugs or preparation of the anti-tumor drugs. Experiments find that nanogel with proper hardness can promote expression of M1 related proteins CD86 and iNOS, and up-regulate expression of CD86 mRNA and iNOS mRNA, so that M2 type tumor related macrophages are reversely polarized into M1 type tumor related macrophages. Further research finds that after the nanogel is used for carrying out reverse polarization treatment on M2 type tumor-related macrophages, tumor cell proliferation can be inhibited, tumor cell apoptosis can be induced, and tumor cell phagocytosis can be realized. In addition, the nanogel with proper hardness is directly delivered into the tumor in an intratumor injection manner, so that the growth of the tumor can be effectively inhibited.

The present application provides the use of drug-loaded lipid nanocarriers in the preparation of drugs for treating drug-resistant lung cancer, wherein the drug-loaded lipid nanocarriers are made of raw materials including lecithin, cholesterol, distearoylphosphatidylethanolamine-polyethylene glycol-amino, osimertinib, and anlotinib hydrochloride, and are modified with EGF. The drug-loaded lipid nanocarriers can be significantly enriched in tumor tissues, effectively inhibit the proliferation of non-small cell lung cancer cells, and effectively reduce the acquired drug resistance of non-small cell lung cancer to EGFR-TKI. In vivo experiments in mice have shown that the nanoliposome drug delivery system has a better tumor inhibition effect than the combination of simple osimertinib and anlotinib.

The invention relates to the technical field of biological medicines, in particular to a recombinant oncolytic virus for expressing a bispecific or trispecific single-chain antibody and application of the recombinant oncolytic virus. The recombinant oncolytic virus comprises an antibody gene integrated into a virus skeleton of the recombinant oncolytic virus; the antibody gene comprises a target antibody gene targeting tumor cells and at least one antibody gene targeting immune cells. When the antibody gene comprises a target antibody gene targeting tumor cells and an antibody gene targeting immune cells, the antibody gene is a bispecific antibody; when the antibody gene comprises a target antibody gene targeting tumor cells and two antibody genes targeting immune cells, the antibody gene is a trispecific antibody. According to the present invention, the coding gene having the bispecific single-chain antibody or the trispecific single-chain antibody is integrated in the modified oncolytic virus, such that the gene of the bispecific single-chain antibody or the trispecific single-chain antibody can be expressed in vivo so as to further improve the tumor cell treatment effect.

The invention discloses a pharmaceutical composition for treating osteosarcoma and application of the pharmaceutical composition, and particularly belongs to the field of biological medicine. The pharmaceutical composition comprises cis-platinum and daidzin, the daidzin provided by the invention is combined with beta-catenin protein, so that the protein stability of the beta-catenin protein is reduced, and a Wnt signal channel is further inhibited, so that the activity of osteosarcoma cells is inhibited, cell apoptosis is induced, and pulmonary metastasis is inhibited; the pharmaceutical composition of cis-platinum and daidzin provided by the invention has a synergistic effect, the sensitivity of cells to cis-platinum is remarkably improved, and the daidzin and cis-platinum combined medication has a remarkable inhibition effect on the activity and migration invasion ability of osteosarcoma cells.

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

The present disclosure relates to a novel peptide for senescence treatment and a use thereof. Specifically, the peptide according to the present disclosure has a binding force with p53 superior to FOXO4 and inhibits the intracellular interaction between p53 and FOXO4, thereby enabling p53 to be released outside the nucleus and moved to mitochondria, inducing apoptosis of aged cells, and selectively inducing apoptosis of aged cells in skin cells.

The invention provides a pharmaceutical composition for treating liver cancer through arterial embolism, the pharmaceutical composition is composed of iodine oil and tirapazamine-loaded nano-vesicles, and the tirapazamine-loaded nano-vesicles comprise nano-vesicles and tirapazamine coated in the inner cores of the nano-vesicles. The invention also provides a preparation method and application of the pharmaceutical composition for treating liver cancer by arterial embolism, the preparation method comprises the following steps: performing liver left artery microcatheter hyperselection on a test rabbit VX2 liver cancer model through in-vivo test, then confirming tumor responsible blood vessels by radiography, and then applying the iodophol and tirapazamine-loaded nano-vesicle compound for embolism until thorough embolism is realized, thereby obtaining the pharmaceutical composition for treating liver cancer by arterial embolism. According to the present invention, the application of the iodophol and the tirapazamine-loaded nano-vesicle compound in the treatment of liver cancer by TAE is safe and effective, the combination with TAE provides the strong synergistic anti-tumor effect, and the TPZ can be promoted to the deep tumor under the action of the UTMD so as to induce the apoptosis of the hypoxia tumor cells;

The invention discloses a photo-thermal and hypoxia dual-sensitive nano carrier material and a preparation method and application thereof, and relates to the field of nano materials, the preparation method comprises the following steps: S1, preparing a carboxymethyl chitosan grafted azobenzene product CMCS-Azo; s2, respectively preparing an L-glutamic acid solution and a carboxymethyl chitosan grafted azobenzene nanoparticle solution, then stirring the L-glutamic acid solution and the carboxymethyl chitosan grafted azobenzene nanoparticle solution for reaction, and performing post-treatment on an obtained reaction solution b to obtain L-Gr-CMCS-Azo; s3, adding the L-Gr-CMCS-Azo into the DMF solution in which the metal compound is dissolved, carrying out ultrasonic treatment and stirring, carrying out post-treatment on the obtained reaction solution c, and finally, carrying out vacuum drying to obtain a solid L-Gr-CMCS-Azo (at) M; and S4, dissolving the L-Grub-CMCS-Azo (at) M material in a DMSO solution, carrying out ultrasonic assisted dissolution, slowly dropwise adding into deionized water, stirring at a low speed, filtering with a microfiltration membrane, and freeze-drying to obtain the nano-carrier material. Therefore, the photo-thermal and hypoxia dual-sensitive nano-carrier material as well as the preparation method and the application thereof are of great significance to the development of anti-cancer therapy.

The invention discloses DUSP23 targeted siRNA and application thereof, and belongs to the technical field of molecular biotechnology and genetic engineering. By researching the expression level of DUSP23 in liver cancer tissues, an action target of the DUSP23 gene is provided for treatment of liver cancer; the invention provides siRNA for inhibiting expression of a human DUSP23 gene and protein and application of the siRNA. The nucleotide sequence of the siRNA is shown as SEQ ID NO.5-SEQ ID NO.6. The invention further provides a preparation method of the siRNA. By transfecting the siRNA in a hepatoma carcinoma cell line, DUSP23 gene and protein expression can be regulated and interfered, cell proliferation and migration ability can be inhibited, cell cycle G0 / G1 phase arrest and cell apoptosis can be induced, and the siRNA has remarkable tumor inhibition activity on transplanted tumor in nude mice of hepatoma carcinoma cells.

The invention belongs to the technical field of anti-tumor drugs, and particularly relates to application of allicin in preparation of an anti-tumor drug sensitizer and a tumor chemotherapy pharmaceutical composition, an A549 cell strain, a paclitaxel drug-resistant cell model A549 / Taxol and a tumor-bearing mouse model are established, and in-vivo and in-vitro pharmacodynamic research finds that the allicin can effectively inhibit cell proliferation and has a good anti-tumor effect. The apoptosis is induced, and the drug resistance of paclitaxel is reversed. The compound inhibits P-gp expression, reduces drug efflux and destroys cell autophagy. Particularly, allicin inhibits cathepsin B (CTSB), destroys lysosome functions, blocks autophagy flux, reduces mitochondrial membrane potential and enhances sensitivity to paclitaxel. The combination of allicin and paclitaxel can significantly inhibit the growth of tumor nodules and reduce the number of tumor nodules, shows the potential of reversing the drug resistance of paclitaxel in vivo, can significantly improve the chemotherapy effect of NSCLC, and has potential clinical application value.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a TGF-beta RI inhibitor in tumor treatment and a pharmaceutical composition of the TGF-beta RI inhibitor. The invention discloses an application of a TGF-beta RI inhibitor single drug or a drug combination in tumor treatment, and the TGF-beta RI inhibitor single drug or the drug combination has a good anti-tumor activity effect, can obviously improve the health condition and the life quality of a patient, and is beneficial to be used as a treatment scheme of advanced or metastatic tumors.

The invention discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors, belongs to the technical field of anti-tumor traditional Chinese medicines, and discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-25 parts of ginseng, 15-18 parts of selfheal, 12-18 parts of seaweed, 12-19 parts of astragalus membranaceus, 10-16 parts of angelica sinensis, 18-30 parts of oldenlandia diffusa, 10-15 parts of fleece-flower root, 10-14 parts of poria cocos, 10-16 parts of thunberg fritillary bulb, 8-14 parts of pseudobulbus cremastrae seu pleiones and 8-17 parts of curcuma zedoary. Through the specific pharmacological action, growth and proliferation of thyroid tumor cells are inhibited, the development speed of tumors can be slowed down, the malignancy degree of the tumors can be reduced, apoptosis of the thyroid tumor cells can be induced, and the number of the tumor cells can be effectively reduced by inducing apoptosis of the tumor cells, so that the anti-tumor purpose is achieved.

The invention relates to the technical field of medical instruments, in particular to a photo-initiation medicine balloon catheter which comprises a catheter body, a balloon fixedly arranged at the far end of the catheter body, a catheter base fixedly arranged at the near end of the catheter body and a plurality of micro spraying pipes fixedly arranged on the outer surface of the balloon. Wherein the catheter main body comprises a first catheter, and a second catheter which is fixedly arranged outside the first catheter in a sleeving manner; wherein a first pipe cavity is formed between the inner wall of the second guide pipe and the outer wall of the first guide pipe, and a plurality of second pipe cavities are arranged between the outer wall of the second guide pipe and the inner wall of the second guide pipe in an annular array mode with the axis of the second guide pipe as the reference; through local administration, the photosensitizer is efficiently activated, the side effects of the whole body are reduced, the treatment effect on diseases such as bile duct cancer is improved, the medical cost is reduced, and the living quality of a patient is also improved.

The invention discloses application of dauricine in preparation of a medicine for treating non-small cell lung cancer, belongs to medical application of the dauricine in the technical field of biological medicines, and creatively discovers that the dauricine has an excellent effect of treating the non-small cell lung cancer. The proliferation of non-small cell lung cancer cells can be inhibited by reducing mitochondrial membrane potential, inhibiting Notch3 protein activity, reducing the expression level of DLL4 protein and the like; meanwhile, a good treatment effect is shown in a non-small cell lung cancer mouse model, growth and proliferation of non-small cell lung cancer cells can be remarkably inhibited, apoptosis of the non-small cell lung cancer cells is induced, depolarization of mitochondria of the non-small cell lung cancer cells is induced, Notch3 protein activity is remarkably inhibited, expression of DLL4 protein is reduced, and the anti-cancer effect is achieved. The invention provides a new path for the application of the dauricine in treating the non-small cell lung cancer, and provides a new thought and strategy for the development and utilization of the dauricine.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded vesicle for treating thyroid cancer as well as a preparation method and application of the drug-loaded vesicle. The drug-loaded vesicle comprises a vesicle, wherein a cavity of the vesicle is loaded with radioactive iodine; the membrane surface of the vesicle is modified with: a) a first single-chain antibody fragment capable of specifically binding to thyroglobulin; according to the present invention, after the intravenous injection, the drug-loaded vesicle can be enriched in the thyroid cancer lesion area of the RAIR-DTC patient, such that the cancer cell proliferation is inhibited while the radioactive iodine is continuously released so as to provide the long-term treatment effect;

The invention discloses an immune reconstruction compound for improving the immune function and preventing and assisting in treating tumors as well as a preparation method and application of the immune reconstruction compound, and relates to the technical field of preparation of related preparations for improving immunity. Comprising 180-220 parts of selenium-enriched garlic powder, 15-25 parts of grifola frondosa extract, 7-13 parts of lucid ganoderma extract, 9-12 parts of cordyceps militaris extract, 14-24 parts of dandelion extract, 17-25 parts of broccoli extract and 8-14 parts of turmeric. The selenium-rich garlic powder is used as a main component, the selenium-rich garlic powder is rich in selenium element, the effects of resisting tumors and improving immunity can be achieved, meanwhile, multiple components including the grifola frondosa extract, the ganoderma lucidum extract, the cordyceps militaris extract, the dandelion extract and the broccoli extract are used as auxiliary materials, and the effects of resisting tumors or preventing tumors are jointly achieved. Meanwhile, the inventor accidentally finds that the selenium-enriched garlic powder, the grifola frondosa extract and the cordyceps militaris extract have a synergistic effect in the experiment process, and the effects of resisting tumors, diminishing inflammation and improving immunity can be remarkably improved by compounding the selenium-enriched garlic powder, the grifola frondosa extract and the cordyceps militaris extract.

The invention discloses a selenium-iron co-doped hydroxyapatite reinforced polylactic acid scaffold and a preparation method thereof, and the preparation method comprises the following steps: co-doping SeO3 < 2-> and Fe < 3 + > into HAP through a co-precipitation method to obtain SF-HAP powder; sF-HAP and PLLA are dispersed in ethyl alcohol, and PLLA / SF-HAP composite powder is obtained through stirring, centrifuging, drying and the like; the PLLA / SF-HAP biological scaffold is prepared through an additive manufacturing technology, in order to endow the PLLA / HAP bone scaffold with an anti-tumor function, Fe is doped into HAP, a Fenton reaction can be promoted in an osteosarcoma environment so that ROS can be generated to kill tumor cells, but overexpressed GSH existing in the tumor cells can consume the ROS to weaken the anti-tumor effect, and doping of Se and Fe can reduce the crystallinity of HAP crystals, so that the anti-tumor effect is improved. The SeO3 < 2-> and the Fe < 3 + > are added into the tumor cells, so that the sustained release of functional ions is facilitated, meanwhile, the consumption of the SeO3 < 2-> and the Fe < 3 + > on the over-expressed GSH and H2O2 in the tumor cells can effectively destroy the redox balance in the tumor cells, and the death of the tumor cells is promoted.

The present application relates to the technical field of biological products, and provides an application of Ganoderma lucidum exosomes in the treatment of brain glioma, an extraction method and a composition, and the application of Ganoderma lucidum exosomes in any one or more of the following: a) preparing a product that promotes apoptosis of brain glioma cells; b) preparing a product that inhibits proliferation of brain glioma cells; c) preparing a product that inhibits autophagy of brain glioma cells; d) preparing a product for treating brain glioma. The present application verifies through cell and animal experiments that Ganoderma lucidum exosomes can effectively induce apoptosis of brain glioma cells and inhibit autophagy of brain glioma cells to induce glioma death, and act on brain glioma cells through the AKT / mTOR signaling pathway and inhibiting the production of autophagosomes in brain glioma cells.

The present invention discloses a composition for improving mitochondrial activity and activating cell energy, and its preparation and medical and cosmetic applications. The composition includes: citrulline, sodium DNA, taurine, arginine / lysine polypeptide, coenzyme Q10, NAD+, creatine, adenosine, ATP, glutamine, inositol, carnosine, glutathione, etc. The present invention activates cells and replenishes energy to improve skin cell vitality from the aspects of improving skin microcirculation, activating mitochondrial function, supplementing nutrition, and maintaining cell metabolism stability through a specific combination. The composition is applied in dermatology to provide energy for important cell functions such as cell renewal and wound repair, and accelerate wound healing; it is applied in skin beauty to fill skin cells with energy, and can effectively improve the volume, depth and area of ​​crow's feet, improve skin roughness, and improve skin elasticity, firmness and glossiness.

The invention relates to application of a traditional Chinese medicine preparation in preparation of a medicine for treating tumor diseases. The traditional Chinese medicine preparation comprises the following raw material medicines in parts by weight: 90-110 parts of sophora flower and 15-25 parts of honeysuckle. The traditional Chinese medicine preparation disclosed by the invention has an obvious inhibition effect on melanoma, can also be used in combination with tumor drugs such as temozolomide, enhances the inhibition effect on melanoma, also can reduce the toxic effect of the drugs on cells, and enhances the immune efficacy of the drugs.

The invention belongs to the technical field of medicines, and particularly relates to application of F919 compounds and salts and stereoisomers thereof in preparation of anti-hepatoma drugs and the anti-hepatoma drugs. The compounds can efficiently inhibit the proliferation capacity of human hepatoma cells, induce arrest and apoptosis of the hepatoma cells in the G0 / G1 period, inhibit the proliferation of the human hepatoma cells and inhibit the proliferation of the human hepatoma cells. The obvious tumor inhibition activity on nude mouse in-situ tumors of liver cancer cells is realized. The invention provides a new medicine for treating the liver cancer, provides an effective method for developing a targeted treatment medicine for treating the liver cancer, and is of great significance for preparing the medicine for treating the liver cancer.

The present invention relates to the field of medical technology, and in particular to an alkoxy-coupled naphthamide derivative and its preparation and application. The chemical structural formula of the alkoxy-coupled naphthamide derivative is shown in Formula I. The alkoxy-coupled naphthamide derivative described in Formula I of the present invention retains the basic skeleton of the binaphthyl structure of gossypol, introduces flexible and easily tortuous atomic chains between naphthalene rings to increase the molecular length, and modifies both ends of the molecule with amino acids, thereby reducing its toxicity, having the advantages of low acute toxicity and high drug safety, having broad-spectrum anti-tumor activity, and can be used as a broad-spectrum anti-tumor drug in clinical application.

The present invention discloses a class of phenyltriazole MLL1-WDR5 protein-protein interaction inhibitors (I) and a preparation method thereof. Pharmacodynamic experiments show that the compounds of the present invention have strong MLL1-WDR5 protein-protein interaction inhibitory activity.

The invention provides application of tanshinone IIA in a carbonic anhydrase inhibitor and a product, and belongs to the field of medicines. According to the application of the tanshinone IIA in the carbonic anhydrase inhibitor, the tanshinone IIA can be combined with carbonic anhydrase to inhibit the activity of the carbonic anhydrase, and the tanshinone IIA can be used in drugs for reducing intraocular pressure, inducing diuresis, correcting metabolic acid / alkali poisoning, increasing vascular oxygen flux, improving pulmonary ventilation, expanding cerebral vessels, inducing tumor cell apoptosis or inhibiting osteoclast bone resorption. The carbonic anhydrase inhibitor can be used for treating carbonic anhydrase-related cardiovascular diseases, altitude sickness, ocular diseases with intraocular hypertension as symptoms, osteoporosis or diseases caused by reduction of bone mineral density, inducing diuresis or correcting metabolic acid / alkali poisoning, and provides reference for design and drug research and development of novel carbonic anhydrase inhibitors. Carbonic anhydrase inhibition drugs with smaller side effects and better curative effects are expected to be developed.

The invention provides application of a madder extract in preparation of a medicine for treating tumors, and relates to the technical field of traditional Chinese medicines. The rubia cordifolia extract is prepared through a water extraction and alcohol precipitation method, and the specific steps comprise soaking, condensation reflux decoction twice, filtering, ethanol precipitation, standing, drying and the like. The rubia cordifolia extract disclosed by the invention can be used for remarkably inhibiting prostate cancer cell proliferation, inducing cell apoptosis and inhibiting metastasis, and has good targeting property and low toxic and side effects. Compared with a traditional treatment medicine, the rubia cordifolia extract disclosed by the invention, as a natural medicine, shows remarkable advantages in the aspects of safety, tolerance and treatment effect, and provides a new potential choice for treatment of urinary system tumors.